Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EEG study of esketamine effects on NMDA-related cortical processing in treatment-resistant depression
NL-OMON61513Not yet recruiting
- Sponsor
- University of Amsterdam
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of esketamine in major depressive disorder (MDD) and treatment-resistant depression (TRD), sponsored by University of Amsterdam. Primary endpoints: Change in task-related EEG markers of cortical feedback processing, Specificity of EEG feedback effects relative to feedforward and lateral processing and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NL-OMON61513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61513.